Feb 29, 2024
Serious headline: Protagonist Therapeutics Inc. Reports Impressive Revenue of $60 Million in Q4 2023 https://csimarket.com/stocks/news.php?code=PTGX&date=2024-02-28150951&utm_source=dlvr.it&utm_medium=tumblr
seen from Russia
seen from United Kingdom
seen from United States
seen from United States
seen from France
seen from United Kingdom
seen from France
seen from United States
seen from Japan
seen from France
seen from France
seen from France
seen from United States
seen from United Kingdom
seen from France
seen from United States
seen from United Kingdom
seen from Malaysia
seen from India
seen from France
Serious headline: Protagonist Therapeutics Inc. Reports Impressive Revenue of $60 Million in Q4 2023 https://csimarket.com/stocks/news.php?code=PTGX&date=2024-02-28150951&utm_source=dlvr.it&utm_medium=tumblr
Analysts See Higher Value for Protagonist Therapeutics Inc (Nasdaq:PTGX), Ending At $11.12
Analysts See Higher Value for Protagonist Therapeutics Inc (Nasdaq:PTGX), Ending At $11.12
Protagonist Therapeutics Inc (Nasdaq:PTGX)
August 6th, 2018
Protagonist Therapeutics Inc finished up $4.11 Friday, a 58.63% jump, closing at $11.12. The stock continues to trade well at 102% of its 52 week low of $5.50. In addition to finishing higher, trading volumes were solid at 2,771% of normal which can indicate investors see opportunities. Be aware that the Altman Z-Score1 (An indicator of…
View On WordPress
4 Stocks To Watch
4 Stocks to Watch
PTGX - Protagonist Therapeutics
PTGX stock gaped up on a new license deal with Johnson & Johnson's Janssen Biotech worth $990 million plus royalties.The stock opened at $12.28 and reached its high of day in the first five minute candle at $14.85. The stock set its low in early morning trading at $11.12 and traded in a range between $11.37 and $12+. PTGX is one of the leading stocks to watch as it has started a new trend and is very bullish over the $12 break. If it cant hold today's low it will fill its gap back down to the $8.50 range.
Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
FENX - Fenix Parts
This is a low volume stock that is currently up-trending and looks poised to test $1.50 resistance level. Buy orders should be placed above $1.50 to capture the potential breakout.
HMNY - Helios and Matheson Analytics
HMNY has filled it gap from its May 23rd gap up and has set a low at $2.50. The original gap up whose high of day reached $4.90 was caused by pre-market buyers after the company announced that it had acquired facial recognition technology licensing rights. Stop losses should be set below the recent $2.50 low and buy on dips. The share float is currently very low at 1.86M so short squeezes can regularly push the share price forward. If $2.50 support holds this can be a good swing to the $4.50-5.00+ level which are viable breakout targets.
Helios & Matheson's stock nearly doubles after acquiring facial recognition technology licensing rights
MNKD - MannKind Corporation
MNKD stock is currently in an uptrend and is poised to breakout of its current chart pattern. $1.75 is the ideal breakout price and its also the prior area where the stock had broken down back on March 28th. This stock remains a priority target on our stocks to watch list.
Click to Post